<DOC>
	<DOCNO>NCT00106691</DOCNO>
	<brief_summary>The purpose study determine toremifene citrate effective safe prevention prostate cancer men diagnose high grade prostatic intraepithelial neoplasia ( PIN ) .</brief_summary>
	<brief_title>Prostate Cancer Prevention Study Men With High Grade PIN ( Prostatic Intraepithelial Neoplasia )</brief_title>
	<detailed_description>The purpose study determine toremifene citrate effective safe prevention prostate cancer men diagnose high grade prostatic intraepithelial neoplasia . Men ever diagnose high grade PIN enrol 36 month trial assign either 20 mg study drug placebo per day . Subjects undergo safety evaluation Month 3 , Month 6 , Month 12 , Month 18 , Month 24 , Month 30 Month 36 along prostate biopsy Month 12 Month 24 Month 36 determine efficacy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Prostatic Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<criteria>Give voluntary sign informed consent accordance institutional policy Be male , age ≥ 30 year Have diagnosis high grade PIN previous prostate biopsy . The diagnosis high grade PIN must confirm central pathologist Have prostate biopsy last 6 month minimum 10 core show evidence cancer confirm central pathologist ; OR , 2 prostate biopsy ( minimum 6 core ) 12 month prior screen least one biopsy occur within 6 month prior screen visit . Both biopsy evidence cancer confirm central pathologist Have serum PSA ≤ 10 ng/mL Agree provide tablet container tablet count Agree use effective method contraception , partner childbearing age , study Have adequate bone marrow , liver renal function : White Blood Cell ( WBC ) Count ≥ 3,000/mm3 ; Platelet Count ≥ 100,000/mm3 ; Bilirubin ≤ 1.5 mg/dL ; AST ALT &lt; 2x upper limit normal ; Serum Creatinine ≤ 2.0 mg % Previous exposure toremifene citrate Have evidence prostate cancer ( local , regional and/or distal metastasis ) Have history malignancy ( exception include nonmelanoma skin cancer cancer evidence tumor reoccurrence , 5 year definitive treatment ) . Superficial bladder cancer acceptable long great 1 year since treatment evidence recurrence . Have active systemic viral , bacterial , fungal infection require treatment Have , judgment investigator , clinically significant concurrent illness psychological , familial , sociological , geographical concomitant condition would permit adequate followup compliance study protocol Concurrently treat investigational agent participate investigational study within 30 day prior screen Currently take dutasteride . Subject eligible stop dutasteride total washout 90 day prior Screening Visit agree use dutasteride duration study . Have previously take finasteride great two year Currently take finasteride . Subject eligible stop finasteride total washout 30 day prior Screening Visit agree use finasteride duration study . Currently take testosterone testosteronelike supplement , dehydroepiandrosterone ( DHEA ) . Subject eligible stop agent total washout 30 day prior Screening Visit agree use agent duration study . Have history take PCSPES within past two year . Currently take herbal medicine dietary supplement prostate health , Saw Palmetto ( also know Serenoa repens ) . Subject eligible stop agent total washout 30 day prior take first dose study drug agree use agent duration study . Lycopene , vitamin E selenium prohibit washout require . However , vitamin E intake limited less 400 i.u . per day . Have history thromboembolic event disease include deep vein thrombosis , pulmonary embolus , thrombotic stroke History chronic hepatitis cirrhosis</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>neoplasia</keyword>
	<keyword>chemoprevention</keyword>
	<keyword>cancer</keyword>
	<keyword>premalignant</keyword>
	<keyword>precancerous</keyword>
	<keyword>Chemoprophylaxis</keyword>
	<keyword>Intraepithelial Prostatic Neoplasia</keyword>
	<keyword>Neoplasia , Prostatic Intraepithelial</keyword>
</DOC>